{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:56:20Z","timestamp":1782305780807,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The precise pathogenesis of immune-related diseases remains unclear, and new effective therapeutic choices are required for the induction of remission or cure in these diseases. Basic research utilizing immune-related disease patient-derived induced pluripotent stem (iPS) cells is expected to be a promising platform for elucidating the pathogenesis of the diseases and for drug discovery. Since autoinflammatory diseases are usually monogenic, genetic mutations affect the cell function and patient-derived iPS cells tend to exhibit disease-specific phenotypes. In particular, iPS cell-derived monocytic cells and macrophages can be used for functional experiments, such as inflammatory cytokine production, and are often employed in research on patients with autoinflammatory diseases.<\/jats:p><jats:p>On the other hand, the utilization of disease-specific iPS cells is less successful for research on autoimmune diseases. One reason for this is that autoimmune diseases are usually polygenic, which makes it challenging to determine which factors cause the phenotypes of patient-derived iPS cells are caused by. Another reason is that protocols for differentiating some lymphocytes associated with autoimmunity, such as CD4<jats:sup>+<\/jats:sup>T cells or B cells, from iPS cells have not been well established. Nevertheless, several groups have reported studies utilizing autoimmune disease patient-derived iPS cells, including patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), and systemic sclerosis. Particularly, non-hematopoietic cells, such as fibroblasts and cardiomyocytes, differentiated from autoimmune patient-derived iPS cells have shown promising results for further research into the pathogenesis. Recently, our groups established a method for differentiating dendritic cells that produce interferon-alpha, which can be applied as an SLE pathological model. In summary, patient-derived iPS cells can provide a promising platform for pathological research and new drug discovery in the field of immune-related diseases.<\/jats:p>","DOI":"10.1186\/s41232-023-00303-4","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T07:02:30Z","timestamp":1698130950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of immune-related diseases using patient-derived induced pluripotent stem cells"],"prefix":"10.1186","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-0303","authenticated-orcid":false,"given":"Hirofumi","family":"Shoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunki","family":"Natsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"303_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(11)70022-9","volume":"10","author":"VB Mattis","year":"2011","unstructured":"Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol. 2011;10:383\u201394.","journal-title":"Lancet Neurol"},{"key":"303_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbior.2018.10.001","volume":"71","author":"H Dolatshad","year":"2019","unstructured":"Dolatshad H, Tatwavedi D, Ahmed D, Tegethoff JF, Boulwood J, Pellagatti A. Application of induced pluripotent stem cell technology for the investigation of hematological disorders. Adv Biol Regul. 2019;71:19\u201333.","journal-title":"Adv Biol Regul."},{"key":"303_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","volume":"29","author":"H Okano","year":"2022","unstructured":"Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29:189\u2013208.","journal-title":"Cell Stem Cell"},{"key":"303_CR4","volume":"13","author":"T Tanaka","year":"2022","unstructured":"Tanaka T, Shiba T, Honda Y, Izawa K, Yasumi T, Saito MK, et al. Induced pluripotent stem cell-derived monocytes\/macrophages in autoinflammatory diseases. Front Immunol. 2022;13: 870535.","journal-title":"Front Immunol"},{"key":"303_CR5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/children8020094","volume":"8","author":"MK Saito","year":"2021","unstructured":"Saito MK. Elucidation of the pathogenesis of autoinflammatory diseases using iPS cells. Children. 2021;8:94.","journal-title":"Children"},{"key":"303_CR6","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731\u20138.","journal-title":"J Immunol"},{"key":"303_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Inoue H, Wu JC, Yamanaka S. Nat Rev Drug Discov. 2017;16:115\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"303_CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40246-020-00276-2","volume":"14","author":"C De Masi","year":"2020","unstructured":"De Masi C, Spitalieri P, Murdocca M, Novellli G, Sangiuolo F. Application of CRISPER\/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics. 2020;14:25.","journal-title":"Hum Genomics"},{"key":"303_CR9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature08320","volume":"461","author":"G Lee","year":"2009","unstructured":"Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009;461:402\u20136.","journal-title":"Nature"},{"key":"303_CR10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12015-012-9388-1","volume":"9","author":"T Inoue-Yokoo","year":"2013","unstructured":"Inoue-Yokoo T, Tani K, Sugiyama D. Mesodermal and hematopoietic differentiation from ES and iPS cells. Stem Cell Rev Rep. 2013;9:422\u201334.","journal-title":"Stem Cell Rev Rep"},{"key":"303_CR11","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood-2009-07-234690","volume":"115","author":"AE Grigoriadis","year":"2010","unstructured":"Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH, et al. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood. 2010;115:2769\u201376.","journal-title":"Blood"},{"key":"303_CR12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-Scale Derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2:274\u201383.","journal-title":"Stem Cells Transl Med"},{"key":"303_CR13","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI42027","volume":"120","author":"H Watarai","year":"2010","unstructured":"Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y, et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest. 2010;120:2610\u20138.","journal-title":"J Clin Invest"},{"key":"303_CR14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue D, Lu S, Zhang H, Zhang L, Dai Z, Kaufman DS, et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trend in Biotech. 2023;41:907\u201322.","journal-title":"Trend in Biotech"},{"key":"303_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","volume":"5","author":"B Wang","year":"2021","unstructured":"Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, et al. Generation of hypoimmunogenic T cells from genetically engineered allogenic human induced pluripotent stem cell. Nat Biomed Eng. 2021;5:429\u201340.","journal-title":"Nat Biomed Eng"},{"key":"303_CR16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928\u201333.","journal-title":"Nat Biotechnol"},{"key":"303_CR17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/stem.33","volume":"27","author":"S Senju","year":"2009","unstructured":"Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cell. Stem Cells. 2009;27:1021\u201331.","journal-title":"Stem Cells"},{"key":"303_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.06.017","volume":"47","author":"K Takata","year":"2017","unstructured":"Takata K, Kozaki T, Lee CZW, Thion MS, Otsuka M, Lim S, et al. Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function. Immunity. 2017;47:183\u201398.","journal-title":"Immunity"},{"key":"303_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.celrep.2019.08.086","volume":"29","author":"N Tsuchiya","year":"2019","unstructured":"Tsuchiya N, Zhang R, Iwama T, Ueda N, Liu T, Tatsumi M, et al. Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritic cells. Cell Rep. 2019;29:162\u201375.","journal-title":"Cell Rep"},{"key":"303_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103085","volume":"139","author":"B Natsumoto","year":"2023","unstructured":"Natsumoto B, Shoda H, Nagafuchi Y, Ota M, Okamura T, Horie Y, et al. Functional evaluation of rare OASL variants by analysis of SLE patient-derived iPSCs. J Autoimmun. 2023;139: 103085.","journal-title":"J Autoimmun"},{"key":"303_CR21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41584-021-00614-1","volume":"17","author":"I Aksentijevich","year":"2021","unstructured":"Aksentijevich I, Schnappauf O. Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases. Nat Rev Rheumatol. 2021;17:405\u201325.","journal-title":"Nat Rev Rheumatol"},{"key":"303_CR22","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2012-03-417881","volume":"120","author":"T Tanaka","year":"2012","unstructured":"Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, et al. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood. 2012;120:1299\u2013308.","journal-title":"Blood"},{"key":"303_CR23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.39960","volume":"69","author":"Y Kawasaki","year":"2017","unstructured":"Kawasaki Y, Oda H, Ito J, Niwa A, Tanaka T, Hijikata A, et al. Identification of a high-frequency somatic NLRC4 mutation as a cause of autoinflammation by pluripotent cell-based phenotype dissection. Arthritis Rheumatol. 2017;69:447\u201359.","journal-title":"Arthritis Rheumatol"},{"key":"303_CR24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaci.2017.04.013","volume":"141","author":"S Takada","year":"2018","unstructured":"Takada S, Kambe N, Kawasaki Y, Niwa A, Honda-Ozaki F, Kobayashi K, et al. Pluripotent stem cell models of Blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages. J Allergy Clin Immunol. 2018;141:339\u201349.","journal-title":"J Allergy Clin Immunol"},{"key":"303_CR25","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1172\/JCI98882","volume":"130","author":"EE Tan","year":"2020","unstructured":"Tan EE, Hopkins RA, Lim CK, Jamuar SS, Ong C, Thoon KC, et al. Dominant-Negative NFKBIA mutation promotes IL-1beta production causing hepatic disease with severe immunodeficiency. J Clin Invest. 2020;130:5817\u201332.","journal-title":"J Clin Invest"},{"key":"303_CR26","doi-asserted-by":"crossref","first-page":"eabf9564","DOI":"10.1126\/sciimmunol.abf9564","volume":"6","author":"T Magg","year":"2021","unstructured":"Magg T, Okano T, Koenig LM, Boehmer DFR, Schwartz SL, Inoue K, et al. Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency. Sci Immunol. 2021;6:eabf9564.","journal-title":"Sci Immunol."},{"key":"303_CR27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","volume":"22","author":"YJ Crow","year":"2022","unstructured":"Crow YJ, Stetson DB. The type I interferonopathies:10 years on. Nat Rev Immunol. 2022;22:471\u201383.","journal-title":"Nat Rev Immunol"},{"key":"303_CR28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.berh.2017.12.002","volume":"31","author":"D Eleftheriou","year":"2017","unstructured":"Eleftheriou D, Brogan PA. Genetic interferonopathies: an overview. Best Pract Res Clin Rheumatol. 2017;31:441\u201359.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"303_CR29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpt.1837","volume":"108","author":"E Genova","year":"2020","unstructured":"Genova E, Cavion F, Lucaf\u00f2 M, Pelin M, Lanzi G, Masneri S, et al. Biomarkers and precision therapy for primary immunodeficiencies: an in vitro study based on induced pluripotent stem cells from patients. Clin Pharmacol Ther. 2020;108:358\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"303_CR30","volume":"41","author":"RM Ferraro","year":"2019","unstructured":"Ferraro RM, Lanzi G, Masneri S, Barisani C, Piovani G, Savio G, et al. Generation of three iPSC lines from fibroblasts of a patient with Aicardi Gouti\u00e8res Syndrome mutated in TREX1. Stem Cell Res. 2019;41: 101580.","journal-title":"Stem Cell Res"},{"key":"303_CR31","volume":"41","author":"RM Ferraro","year":"2019","unstructured":"Ferraro RM, Masneri S, Lanzi G, Barisani C, Piovani G, Savio G, et al. Establishment of three iPSC lines from fibroblasts of a patient with Aicardi Gouti\u00e8res syndrome mutated in RNaseH2B. Stem Cell Res. 2019;41: 101620.","journal-title":"Stem Cell Res"},{"key":"303_CR32","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.scr.2019.101623","volume":"41","author":"S Masneri","year":"2019","unstructured":"Masneri S, Lanzi G, Ferraro RM, Barisani C, Piovani G, Savio G, et al. Generation of three isogenic induced Pluripotent Stem Cell lines (iPSCs) from fibroblasts of a patient with Aicardi Gouti\u00e8res Syndrome carrying a c.2471G>A dominant mutation in IFIH1 gene. Stem Cell Res. 2019;41:101623.","journal-title":"Stem Cell Res."},{"key":"303_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101697","volume":"43","author":"NV Fuchs","year":"2020","unstructured":"Fuchs NV, Schieck M, Neuenkirch M, Tondera C, Schmitz H, Wendeburg L, et al. Generation of three induced pluripotent cell lines (iPSCs) from an Aicardi-Gouti\u00e8res syndrome (AGS) patient harboring a deletion in the genomic locus of the sterile alpha motif and HD domain containing protein 1 (SAMHD1). Stem Cell Res. 2020;43: 101697.","journal-title":"Stem Cell Res"},{"key":"303_CR34","volume":"64","author":"V H\u00e4nchen","year":"2022","unstructured":"H\u00e4nchen V, Kretschmer S, Wolf C, Engel K, Khattak S, Neumann K, et al. Generation of induced pluripotent stem cell lines from three patients with Aicardi-Gouti\u00e8res syndrome type 5 due to biallelic SAMDH1 mutations. Stem cell Res. 2022;64: 102912.","journal-title":"Stem cell Res"},{"key":"303_CR35","volume":"64","author":"V H\u00e4nchen","year":"2022","unstructured":"H\u00e4nchen V, Kretschmer S, Wolf C, Engel K, Khattak S, Neumann K, et al. Generation of induced pluripotent stem cell lines from two patients with Aicardi-Gouti\u00e8res syndrome type 1 due to biallelic TREX1 mutations. Stem Cell Res. 2022;64: 102895.","journal-title":"Stem Cell Res"},{"key":"303_CR36","volume":"50","author":"L Barnabei","year":"2020","unstructured":"Barnabei L, Castela M, Banal C, Lefort N, Rieux-Laucat F. Generation of an iPSC line (IMAGINi011-A) from a patient carrying a STING mutation. Stem Cell Res. 2020;50: 102107.","journal-title":"Stem Cell Res"},{"key":"303_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2022.102974","volume":"65","author":"A Mehta","year":"2022","unstructured":"Mehta A, Yu Q, Liu Y, Yang D, Zou J, Beers J, et al. Human induced pluripotent stem cells generated from STING-associated vasculopathy with onset in infancy (SAVI) patients with a heterozygous mutation in the STING gene. Stem Cell Res. 2022;65: 102974.","journal-title":"Stem Cell Res"},{"key":"303_CR38","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.stemcr.2018.04.004","volume":"10","author":"F Honda-Ozaki","year":"2018","unstructured":"Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, et al. Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress. Stem Cell Reports. 2018;10:1835\u201350.","journal-title":"Stem Cell Reports"},{"key":"303_CR39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/sctm.20-0198","volume":"10","author":"N Kase","year":"2021","unstructured":"Kase N, Terashima M, Ohta A, Niwa A, Honda-Ozaki F, Kawasaki Y, et al. Pluripotent stem cell-based screening identifies CUDC-907 as an effective compound for restoring the in vitro phenotype of Nakajo-Nishimura syndrome. Stem Cells Trans Med. 2021;10:455\u201364.","journal-title":"Stem Cells Trans Med"},{"key":"303_CR40","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri3850","volume":"15","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15:429\u201340.","journal-title":"Nat Rev Immunol."},{"key":"303_CR41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Sanchez GAM, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507\u201318.","journal-title":"N Engl J Med"},{"key":"303_CR42","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1073\/pnas.1106015108","volume":"108","author":"K Arima","year":"2011","unstructured":"Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T, Mizushima T, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A. 2011;108:14914\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"303_CR43","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1172\/JCI58414","volume":"121","author":"A Kitamura","year":"2011","unstructured":"Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011;121:4150\u201360.","journal-title":"J Clin Invest"},{"key":"303_CR44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS. Pathogenesis of autoimmune diseases. Net Rev Nephrol. 2023;19:509\u201324.","journal-title":"Net Rev Nephrol"},{"key":"303_CR45","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primer. 2016;2:16039.","journal-title":"Nat Rev Dis Primer"},{"key":"303_CR46","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ng.3885","volume":"49","author":"K Ishigaki","year":"2017","unstructured":"Ishigaki K, Kochi Y, Suzuki A, Tsuchida Y, Tsuchiya H, Sumitomo S, et al. Polygenic burdens on cell-specific pathway underlie the risk of rheumatoid arthritis. Nat genet. 2017;49:1120\u20135.","journal-title":"Nat genet"},{"key":"303_CR47","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","volume":"184","author":"M Ota","year":"2021","unstructured":"Ota M, Nagafuchi Y, Hatano H, Ishigaki K, Terao C, Takeshima Y, et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell. 2021;184:3006\u201321.","journal-title":"Cell."},{"key":"303_CR48","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/ar4470","volume":"16","author":"J Lee","year":"2014","unstructured":"Lee J, Kim Y, Yi H, Diecke S, Kim J, Jung H, et al. Generation of disease-specific induced pluripotent stem cells from patients with rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2014;16:R41.","journal-title":"Arthritis Res Ther"},{"key":"303_CR49","first-page":"54072","volume":"116","author":"YA Rim","year":"2016","unstructured":"Rim YA, Park N, Nam Y, Ju JH. Generation of induced-pluripotent stem cells using fibroblast-like synoviocytes isolated from joints of rheumatoid arthritis patients. J Vis Exp. 2016;116:54072.","journal-title":"J Vis Exp"},{"key":"303_CR50","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2022.102886","volume":"64","author":"J Wolnik","year":"2022","unstructured":"Wolnik J, Kubiak G, Skoczy\u0144ska M, Wiland P, Fearon U, Veale D, et al. Generation of two hiPSC lines, (DMBi003-A and DMBi004-A), by reprogramming peripheral blood mononuclear cells and fibroblast-like synoviocytes from rheumatoid arthritis patients. Stem Cell Res. 2022;64: 102886.","journal-title":"Stem Cell Res"},{"key":"303_CR51","doi-asserted-by":"crossref","first-page":"32669","DOI":"10.1038\/srep32669","volume":"6","author":"J Lee","year":"2016","unstructured":"Lee J, Jung SM, Ebert AD, Wu H, Diecke S, Kim Y, et al. Generation of functional cardiomyocytes from the synoviocytes of patients with rheumatoid arthritis via induced pluripotent stem cells. Sci Rep. 2016;6:32669.","journal-title":"Sci Rep"},{"key":"303_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13287-019-1408-5","volume":"10","author":"J Kim","year":"2019","unstructured":"Kim J, Kang SC, Yoon NE, Kim Y, Choi J, Park N, et al. Metabolomic profiles of induced pluripotent stem cells derived from patients with rheumatoid arthritis and osteoarthritis. Stem Cell Res Ther. 2019;10:319.","journal-title":"Stem Cell Res Ther"},{"key":"303_CR53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13287-018-1100-1","volume":"9","author":"J Kim","year":"2018","unstructured":"Kim J, Kim Y, Choi J, Jung H, Lee K, Kang J, et al. Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepatocytes from patients with rheumatoid arthritis. Stem Cell Res Ther. 2018;9:357.","journal-title":"Stem Cell Res Ther"},{"key":"303_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10067-016-3469-5","volume":"36","author":"G Layh-Schmitt","year":"2017","unstructured":"Layh-Schmitt G, Lu S, Navid F, Brooks SR, Lazowick E, Davis KM, et al. Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. Clin Rheumatol. 2017;36:143\u201354.","journal-title":"Clin Rheumatol"},{"key":"303_CR55","volume":"45","author":"J Hu","year":"2020","unstructured":"Hu J, Ren W, Qiu W, Lv J, Zhang C, Xu C, et al. Generation of induced pluripotent stem cell line (XDCMHi001-A) from an ankylosing spondylitis patient with JAK2 mutation. Stem Cell Res. 2020;45: 101788.","journal-title":"Stem Cell Res"},{"key":"303_CR56","volume":"46","author":"J Hu","year":"2020","unstructured":"Hu J, Lu C, Zhu W, Jiang Q, Du W, Wu N. Establishment of an induced pluripotent stem cell line (SHFDi001-A) from a patient with ankylosing spondylitis. Stem Cell Res. 2020;46: 101879.","journal-title":"Stem Cell Res"},{"key":"303_CR57","volume":"48","author":"MY Son","year":"2016","unstructured":"Son MY, Lee MO, Jeon H, Seol B, Kim JH, Chang JS, et al. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Exp Mol Med. 2016;48: e232.","journal-title":"Exp Mol Med"},{"key":"303_CR58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/scd.2016.0181","volume":"26","author":"MY Son","year":"2017","unstructured":"Son MY, Kim YD, Seol B, Lee MO, Na HJ, Yoo B, et al. Biomarker discovery by modeling Beh\u00e7et\u2019s disease with patient-specific human induced pluripotent stem cells. Stem Cell Dev. 2017;26:133\u201345.","journal-title":"Stem Cell Dev"},{"key":"303_CR59","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.stemcr.2017.04.010","volume":"8","author":"M Iizuka-Koga","year":"2017","unstructured":"Iizuka-Koga M, Asashima H, Ando M, Lai CY, Mochizuki S, Nakanishi M, et al. Functional analysis of dendritic cells generated from T-iPSCs from CD4+ T cell clones of Sj\u00f6gren\u2019s syndrome. Stem Cell Reports. 2017;8:1155\u201363.","journal-title":"Stem Cell Reports"},{"key":"303_CR60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jdermsci.2016.08.002","volume":"84","author":"Z Wang","year":"2016","unstructured":"Wang Z, Nakamura K, Jinnin M, Kudo H, Goto M, Era T, et al. Establishment and gene expression analysis of disease-derived induced pluripotent stem cells of scleroderma. J Dermatol Sci. 2016;84:186\u201396.","journal-title":"J Dermatol Sci"},{"key":"303_CR61","first-page":"273","volume":"23","author":"S Gholami","year":"2021","unstructured":"Gholami S, Mazidi Z, Pahlavan S, Moslem F, Hosseini M, Taei A, et al. A Novel insight into endothelial and cardiac cells phenotype in systemic sclerosis using patient-derived induced pluripotent stem cell. Cell J. 2021;23:273\u201387.","journal-title":"Cell J"},{"key":"303_CR62","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00296-013-2704-5","volume":"33","author":"Y Chen","year":"2013","unstructured":"Chen Y, Luo R, Xu Y, Cai X, Li W, Tan K, et al. Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumtaol Int. 2013;33:2127\u201334.","journal-title":"Rheumtaol Int"},{"key":"303_CR63","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12864-016-2809-9","volume":"17","author":"D Tang","year":"2016","unstructured":"Tang D, Chen Y, He H, Huang J, Chen W, Peng W, et al. Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine. BMC Genomics. 2016;17:488.","journal-title":"BMC Genomics"},{"key":"303_CR64","doi-asserted-by":"crossref","first-page":"7382","DOI":"10.1111\/jcmm.14598","volume":"23","author":"MT De Angelis","year":"2019","unstructured":"De Angelis MT, Santamaria G, Parrotta EI, Scalise S, Lo Conte M, Gasparini S, et al. Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus. J Cell Mol Med. 2019;23:7382\u201394.","journal-title":"J Cell Mol Med"},{"key":"303_CR65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.15283\/ijsc21158","volume":"15","author":"N Park","year":"2022","unstructured":"Park N, Rim YA, Jung H, Nam Y, Ju JH. Lupus heart disease modeling with combination of induced pluripotent stem cell-derived cardiomyocytes and lupus patient serum. S Int J Stem Cells. 2022;15:233\u201346.","journal-title":"S Int J Stem Cells"},{"key":"303_CR66","volume":"51","author":"D Li","year":"2021","unstructured":"Li D, Hong X, Li W, Meng S, Yu H, Zhang X, et al. Establishment of an induced pluripotent stem cell line SPHi001-A from a systemic lupus erythematosus patient combined with preeclampsia and psoriasis. Stem Cell Res. 2021;51: 102192.","journal-title":"Stem Cell Res"},{"key":"303_CR67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/scd.2020.0194","volume":"30","author":"W Li","year":"2021","unstructured":"Li W, Liu D, Zheng F, Zeng Z, Cai W, Luan S, et al. Generation of systemic lupus erythematosus patient-derived induced pluripotent stem cells from blood. Stem cells Dev. 2021;30:227\u201333.","journal-title":"Stem cells Dev"},{"key":"303_CR68","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid arthritis-common origins, divergent mechanisms. N Engl J Med. 2023;388:529\u201342.","journal-title":"N Engl J Med"},{"key":"303_CR69","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563\u201374.","journal-title":"N Engl J Med"},{"key":"303_CR70","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjogren syndrome Nat Rev Dis Primer. 2016;2:16047.","journal-title":"Sjogren syndrome Nat Rev Dis Primer"},{"key":"303_CR71","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2013","unstructured":"Volkmann ER, Andreasson K, Smith V. Systemic sclerosis. Lancet. 2013;401:304\u201318.","journal-title":"Lancet"},{"key":"303_CR72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-023-36306-5","volume":"14","author":"C Khunsriraksakul","year":"2023","unstructured":"Khunsriraksakul C, Li Q, Markus H, Patrick MT, Sauteraud R, McGuire D, et al. Multi-ancestry and multi-trait genome-wide association meta-analyze inform clinical risk prediction for systemic lupus erythematosus. Nat Commun. 2023;14:668.","journal-title":"Nat Commun"},{"key":"303_CR73","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3389\/fimmu.2018.02496","volume":"9","author":"JM Alperin","year":"2018","unstructured":"Alperin JM, Ortix-Fernandez L, Sawalha AH. Monogenic lupus: a developing paradigm of disease. Front Immunol. 2018;9:2496.","journal-title":"Front Immunol"},{"key":"303_CR74","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"303_CR75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang Z, McWillliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR+iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29:515\u201327.","journal-title":"Cell Stem Cell"},{"key":"303_CR76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41551-022-00969-0","volume":"7","author":"T Ueda","year":"2023","unstructured":"Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023;7:24\u201337.","journal-title":"Nat Biomed Eng"},{"key":"303_CR77","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1111\/febs.16162","volume":"289","author":"H Tsujimoto","year":"2022","unstructured":"Tsujimoto H, Osafune K. Current status and future directions of clinical applications using iPS cells-focus on Japan. FEBS J. 2022;289:7274\u201391.","journal-title":"FEBS J"}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-023-00303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-023-00303-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-023-00303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:09:10Z","timestamp":1700338150000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-023-00303-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1186\/s41232-023-00303-4","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KF received consulting honoraria and research support from Chugai Pharmaceutical. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}